Introduction {#Sec1}
============

Preeclampsia is a multisystem disorder characterized by maternal hypertension and end-organ damage, complicating 3--4% of pregnancies^[@CR1],[@CR2]^. About 10--16% of all maternal deaths are related to preeclampsia^[@CR3]--[@CR5]^. Abnormal trophoblast invasion and endothelial dysfunction is the main participants in the pathogenesis of preeclampsia. In placentas of preeclamptic women, endothelial damage and lipid accumulation in myointimal cells and macrophages, which is atherosis, is more common finding, resulting in abnormally narrow spiral arterioles and subsequent impaired placental perfusion^[@CR6]^.

The increased level of circulating lipids may result in accelerated accumulation within endothelial cell. In previous reports, preeclamptic patients showed higher serum levels of triglycerides, total cholesterol and low-density lipoprotein cholesterol (LDL-C) than normal pregnant women^[@CR7],[@CR8]^, whereas the relationship between dyslipidemia and preeclampsia was not consistent in other studies^[@CR9],[@CR10]^. In addition to lipoprotein concentrations, the levels of endogenous and exogenous sterols reflect cholesterol metabolism, including biosynthesis (cholesterol precursors), degradation (hydroxycholesterols) and absorption (plant sterols)^[@CR11]^. In our previous study, the association between cholesterols and lipid profiles was observed^[@CR12]^, and understanding the mechanisms underlying cholesterol metabolism may implicate pathophysiology and therapeutic response to dyslipidemias and metabolic syndrome^[@CR13],[@CR14]^.

Due to quantitative analysis of cholesterol precursors and metabolites provides insight into metabolic signatures of cholesterol, we evaluated the metabolic profiling in both maternal plasma and amniotic fluid (AF) obtained from pregnant women who delivered in the late preterm period because of preeclampsia and compared these results to that measured in women who delivered at a comparable gestational age due to spontaneous preterm labor or a maternal medical indication. We evaluated whether metabolic signature suggesting cholesterol biosynthesis and accumulation pathway be altered in women with preeclampsia.

Materials and Methods {#Sec2}
=====================

Study design {#Sec3}
------------

In this retrospective cohort study, consecutive singleton pregnant women who delivered in the late preterm period (34-0/7--36-6/7 weeks) and who met the following criteria were included: (1) clinically-indicated amniocentesis within 3 days of delivery; (2) no evidence of rupture of membranes; (3) no evidence of intra-amniotic infection/inflammation in the AF; and (4) no antenatal corticosteroids prior to amniocentesis. Cases with twin pregnancy, a major fetal structural anomaly or aneuploidy, or intrauterine fetal death were excluded. This study was approved by the Institutional Review Board of the Seoul National University Hospital (Approval Number 1606-051-770), and patients provided written informed consent for the sample collections and use of biologic materials for research purposes. And all experiments were performed in accordance with relevant guidelines and regulations.

Etiology of late preterm birth {#Sec4}
------------------------------

Patients were classified into 3 groups according to the etiology of their preterm birth: Group 1, preeclampsia; Group 2, spontaneous preterm labor; Group 3, other maternal medical indications for iatrogenic preterm birth. Preeclampsia and the severity of preeclampsia were diagnosed using standardized criteria suggested by the American College of Obstetricians and Gynecologists^[@CR1]^. Briefly, preeclampsia was defined as hypertension during late pregnancy and evidence of multiorgan involvement including proteinuria, thrombocytopenia, renal dysfunction, liver involvement, central nervous system perturbations, or pulmonary edema.

Sample collection and preparation {#Sec5}
---------------------------------

Amniocentesis was done prior to preterm delivery by transabdominal amniocentesis or at the time of cesarean delivery (by inserting a needle into the fetal membranes and withdrawing fluid under direct visualization)^[@CR15]^. In all cases, the amniocentesis was clinically indicated to determine the presence or absence of intra-amniotic infection/inflammation or to document fetal lung maturity. Amniotic fluid was cultured for aerobic and anaerobic bacteria as well as for genital mycoplasmas, and was examined in the hemocytometer chamber to determine the white blood cell (WBC) count. Cases with positive AF culture (intra-amniotic infection) or with intra-amniotic inflammation (defined as an AF WBC ≥19/mm^3^ as previously reported^[@CR16],[@CR17]^), were excluded from the analysis. At the time of amniocentesis, maternal venous blood samples were obtained, and collected into tubes containing EDTA. The AF and maternal plasma samples were centrifuged at 2,000 rpm for 10 min and stored at −70 °C until assayed.

Chemicals {#Sec6}
---------

All reference standards were obtained from Steraloids (Newport, RI, USA). Other chemicals included the deuterium-labeled internal standards (ISs), 2,2,3,4,4,6-*d*~6~-cholesterol and 2,2,3,4,4,6-*d*~6~-cholesteryl stearate (C/D/N Isotopes, Pointe-Claire, Quebec, Canada) for cholesterol, plant sterols and cholesteryl esters (CEs), respectively, and 25,26,26,26,27,27,27-*d*~7~-4β-hydroxycholesterol and 25,26,26,26,27,27,27-*d*~7~-27-hydroxycholesterol (Avanti Polar Lipids, Alabaster, AL, USA) for 3 cholesterol precursors and 8 hydroxycholesterols (OHCs). For trimethylsilylation (TMS), *N*-methyl-*N*-trifluorotrimethylsilyl acetamide (MSTFA), ammonium iodide (NH~4~I), and dithioerythritol (DTE) were purchased from Sigma (St. Louis, MO, USA). The hybrid SPE-precipitation cartridge (H-PPT, 1 mL, 30 mg) was supplied by Supelco (Bellefonte, PA, USA). All organic solvents were of analytical and HPLC grades and were purchased from Burdick & Jackson (Muskegon, MI, USA).

Metabolic signatures of cholesterol {#Sec7}
-----------------------------------

Quantitative metabolite profiling of cholesterols was performed using gas chromatography-mass spectrometry as previously reported^[@CR18],[@CR19]^. Briefly, samples of serum (20 μL) and AF (50 μL) were spiked with 20 μL of the IS mixtures (*d*~6~-cholesterol and *d*~6~-cholesteryl stearate; 100 μg/mL, *d*~7~-4β-hydroxycholesterol and *d*~7~-27-hydroxycholesterol; 20 ng/mL) and added to 0.5 mL methanol. The mixture was vortexed for 5 min and centrifuged for 2 min at 12,000 rpm for protein precipitation. Samples were then loaded into H-PPT cartridges and eluted 3 times with 0.5 mL of methanol. The combined eluate was evaporated under an N~2~ evaporator at 40 °C and dried in a vacuum desiccator over P~2~O~5~/KOH for 30 min. The dried residues were derivatized with 40 μL of MSTFA/NH~4~I/DTE (500:4:2, v/w/w) for 20 min at 60 °C, and 2 μL of the resulting mixture was injected into the GC-MS system.

GC-MS analysis {#Sec8}
--------------

GC-MS was performed with an Agilent 6890 Plus gas chromatograph interfaced with a single-quadrupole Agilent 5975C MSD (Agilent Technologies; Palo Alto, CA, USA). Each sample (2 μL) was injected in split mode (10:1) at 300 °C and separated through a MXT-5 capillary column (15 m × 0.25 mm I.D., 0.25 μm film thickness, Silcosteel-treated stainless steel; Restek; Bellefonte, PA, USA). The oven temperature was initially held at 265 °C for 5 min, then increased to 280 °C at a rate of 2 °C/min, and finally increased to 380 °C at 5 °C/min (held for 3 min). The carrier gas was ultra-high-purity helium at a column head pressure of 89.6 kPa (13 psi; column flow: 1.1 mL/min at an oven temperature of 265 °C).

Statistical analysis {#Sec9}
--------------------

The calibration curve consisted of a blank sample (matrix sample processed without internal standards), a zero sample (matrix sample processed with internal standards), and 11 calibrators from LOQ to the expected range in the sample. Good linear regression results in a two-curves calibration standard per concentration level were achieved for all compounds analyzed with the higher correlation coefficient (r^2^) than 0.99. Quantitative results for individual sterols and their metabolic ratios, which were calculated by dividing the concentration of the substrate by the concentration of its metabolite (an indicator of enzyme activity), are expressed as means ± standard deviation (SD). Continuous data were analyzed using the Mann-Whitney U test or Kruskal-Wallis test, and categorical data were analyzed with Fisher's exact test or Chi-square test as appropriate. Statistical analyses were conducted using the IBM SPSS version 20. *P* \< 0.05 was considered statistically significant.

Results {#Sec10}
=======

Study population {#Sec11}
----------------

A total of 39 women met the inclusion criteria and were included in the final analysis; 14 with preeclampsia (Group 1), 16 with spontaneous preterm labor (Group 2), and 9 with other maternal medical indications for iatrogenic preterm birth (Group 3). In Group 1, 11 cases were diagnosed with severe preeclampsia and 3 with non-severe preeclampsia, according to the ACOG standardized criteria^[@CR1]^. In Group 3, the indications for iatrogenic preterm birth were critical maternal medical disease (n = 4), maternal physical discomfort (n = 2, osteogenesis imperfecta in 1 case and intractable back pain in 1 case), poorly controlled maternal depression (n = 1), and maternal request for late preterm delivery due to history of prior intrauterine fetal death after confirmation of fetal lung maturity (n = 2).

Table [1](#Tab1){ref-type="table"} shows the clinical characteristics of the study population according to the etiology of the late preterm birth. Maternal age, parity, and gestational age at delivery were not significantly different among the three groups. However, the fetuses of women with preeclampsia (Group 1) had significantly lower birthweight than those in Groups 2 and 3.Table 1Characteristics of the study population according to the etiology of the late preterm birth.Group 1P^a^Group 2P^b^Group 3P^c^P^d^Preeclampsia (n = 14)Preterm labor (n = 16)Other maternal-fetal indication (n = 9)Maternal age (years)30.9 ± 4.10.49832.3 ± 3.80.63732.4 ± 2.80.2770.527Nulliparity7 (50%)0.4575 (31%)0.3641 (11%)0.0860.151Pre-gestational body-mass index (kg/m^2^)21.9 ± 3.2 (n = 9)0.55220.5 ± 3.1 (n = 11)0.06224.5 ± 4.0 (n = 6)0.2720.167Gestational age at amniocentesis (weeks)35.7 ± 1.10.98435.7 ± 0.80.67735.9 ± 0.80.6880.882Gestational age at delivery (weeks)35.7 ± 1.10.98435.7 ± 0.80.76035.9 ± 0.70.7810.940Birth weight (g)2278 ± 5860.0702634 ± 4720.3012798 ± 290**0.0130.031**Small for gestational age2 (14%)0.5861 (6%)1.0000 (0%)0.5020.437Sex (male)7 (50%)1.0008 (50%)0.6773 (33%)0.6690.679Diabetes during pregnancy0 (0%)1.0001 (6%)1.0001 (11%)0.3910.482Cesarean delivery14 (100%)0.10312 (75%)0.2609 (100%)(−)**0.041**\*All values are given as mean ± standard deviation.P^a^: Comparison between groups 1 and 2.P^b^: Comparison between groups 2 and 3.P^c^: Comparison between groups 1 and 3 P^d^: Comparison among groups 1, 2 and 3.

Cholesterol signatures in maternal blood {#Sec12}
----------------------------------------

Patients in Group 1 had significantly higher ratios of cholesterol/desmosterol and cholesterol/7-dehydrocholesterol, representing 24- and 7-reductase enzyme activity, respectively, than those in Group 3 (p \< 0.05 for each, Table [2](#Tab2){ref-type="table"}). This suggests increased cholesterol biosynthesis. In contrast, patients in Group 1 had the lower ratios of individual cholesterol esters/cholesterol and total cholesterol esters/cholesterol than those in Group 3 (p \< 0.01 for each), suggesting increased reverse cholesterol transport.Table 2Metabolite profiling of cholesterols in maternal serum samples.Group 1 Preeclampsia (n = 14)Group 2 Preterm labor (n = 16)Group 3 Other maternal-fetal indication (n = 9)K-W testMann Whitney U testmeanSDmeanSDmeanSDp-valueGroup 1 vs. 2Group 1 vs. 3Group 2 vs. 3***Concentration (μg/mL)***Cholesterol588.4215.7599.3165.0529.7117.90.6860.7590.7340.357Cholesterol laurate1.80.41.90.52.83.20.9370.8860.9260.677Cholesterol myristate52.540.254.125.845.320.90.5490.3130.9260.487Cholesterol palmitate736.8534.3627.2355.8509.8184.00.8520.9510.5570.718Cholesterol oleate, linoleate & stearate1460.9558.01587.0442.61571.2443.70.7570.5800.5160.934Cholesterol arachidonate371.5229.0383.0172.3341.1118.50.7870.5250.6880.890∑Chol-O, Li, S, A1832.4749.41970.0526.31912.2528.90.8630.6080.7810.934∑Cholesterol esters2623.51255.12653.2726.52470.1650.80.8300.4980.9750.890Sitosterol3.11.73.50.83.20.60.2720.1540.6000.276Campesterol2.81.12.80.82.81.20.7580.5800.7340.522Stigmasterol1.40.61.40.11.40.00.1770.2570.2500.890***Concentration (ng/mL)***Desmosterol145.648.5177.374.8172.862.10.2930.1660.2241.0007-Dehydrocholesterol170.658.5201.179.5203.457.10.3160.2570.1790.718Lathosterol962.8764.31005.7524.9883.1266.70.7960.5800.7340.677Lanosterol89.931.9102.833.8104.645.00.3440.1660.3690.7187α-OHC235.2132.9266.3242.6197.886.90.8430.8220.5160.8467β-OHC163.972.1179.3136.6140.646.50.7990.7590.4030.9784β-OHC29.49.732.712.127.57.50.6420.6670.6000.38827-OHC28.58.128.27.125.14.70.7530.9180.5160.52224-OHC9.37.29.35.76.32.70.5160.4000.7810.329***Metabolic ratios*Chol/Desmo4.0320.6893.5460.6293.2730.974**0.0610.058**0.039**0.637**Chol/7-DHC3.4400.5323.0930.5082.7140.7400.028**0.058**0.019**0.2077-DHC**/**Latho0.2520.1800.2400.1280.2420.0750.6871.0000.4770.452Latho**/**Lano9.7124.2059.4433.2868.9652.3830.9400.9180.6880.934Desmo**/**Lano1.6790.4931.7270.4471.8100.7550.7730.5800.6000.760Chol**/**Lano6.6931.9335.9881.2225.5601.9690.2710.3550.1590.329Sito\*1000**/**Chol5.7551.3956.1521.8556.2421.2100.7550.7590.4770.677Campe\*1000**/**Chol4.8221.1374.9131.5375.2181.2150.7260.9840.4390.559Stigma\*1000/ Chol2.6530.9412.5420.7332.7610.7600.6910.9180.6430.357Campe/ Sito0.8530.1650.8130.1830.8460.1770.7550.4480.9750.718Stigma/ Sito0.4530.0740.4190.0550.4410.0610.2490.1540.6430.2077α-OHC/ Chol0.3980.1880.4530.3750.3580.1190.8520.6970.6000.8037β-OHC/ Chol0.2840.0960.3020.1920.2600.0400.8760.7280.6880.7187α-OHC/ 7β-OHC1.3440.3301.3280.4091.3440.3080.9430.7280.9750.8904β-OHC/ Chol0.0510.0110.0550.0140.0520.0060.4910.3130.7340.38827-OHC/ Chol0.0510.0110.0500.0190.0480.0070.4380.2940.9260.30124-OHC/Chol0.0140.0070.0150.0060.0120.0050.4130.6080.4770.187Chol-L**/**Chol0.0030.0010.0030.0010.0050.0050.5660.9510.4030.329Chol-M**/**Chol0.0820.0400.0900.0360.0830.0280.8900.6370.9260.846Chol-P**/**Chol1.2050.5371.0600.4950.9910.3630.5720.5520.2500.890**Chol-O, Li & S/Chol2.4720.2442.6930.4672.9320.3370.022**0.093**0.005**0.229Chol-A**/**Chol0.6090.2130.6350.2070.6310.1730.8470.7280.5570.978**∑Chol-O, Li, S, A/Chol3.0810.3443.3280.4693.5630.4170.020**0.085**0.007**0.169∑Cholesterol esters/Chol4.3710.8014.4820.7514.6420.6160.5790.6970.3360.487NS, not significant.

In the study population, there are 2 women with diabetes. The altered metabolic signature (higher ratios of cholesterol/desmosterol and cholesterol/7-dehydrocholesterol, and lower ratios of individual cholesterol esters/cholesterol and total cholesterol esters/cholesterol in Group 1 than those in Group 3) remained significant, even after excluding 2 cases with diabetes.

Metabolite profiling in amniotic fluid {#Sec13}
--------------------------------------

No differences in metabolite profiling of cholesterol were found in AF among the 3 groups (Table [3](#Tab3){ref-type="table"}).Table 3Metabolite profiling of cholesterols in amniotic fluid.Group 1 Preeclampsia (n = 14)Group 2 Preterm labor (n = 16)Group 3 Other maternal-fetal indication (n = 9)K-W testmeanSDmeanSDmeanSDp-value***Concentration (μg/mL)***Cholesterol2.40.73.85.52.10.50.785Cholesterol laurate0.40.00.40.00.40.01.000Cholesterol myristate0.70.10.70.10.70.00.454Cholesterol palmitate1.80.41.70.61.70.30.627Cholesterol oleate, linoleate & stearate2.00.41.80.62.10.40.286Cholesterol arachidonateND^a^---ND---ND---NA^b^∑Cholesterol esters4.51.04.41.34.60.60.508Sitosterol0.20.030.20.00.20.10.373CampesterolND---0.20.00.20.01.000Stigmasterol0.20.00.20.00.20.01.000***Concentration (ng/mL)***Desmosterol31.07.732.810.029.94.60.7687-Dehydrocholesterol21.61.323.25.521.91.20.492Lathosterol71.136.793.890.250.25.80.770Lanosterol22.612.722.416.213.63.20.5007α-OHC3.51.63.52.13.22.50.7607β-OHC2.51.02.81.22.41.10.7144β-OHCND---ND---ND---NA27-OHCND---ND---ND---NA24-OHCND---ND---ND---NA***Metabolic ratios***Chol**/**Desmo0.0810.0330.0980.0900.0730.0270.825Chol**/**7-DHC0.1100.0320.1370.1290.0970.0270.7457-DHC**/**Latho0.3650.1440.3520.1560.4410.0510.502Latho**/**Lano3.6180.8954.2711.5203.8510.8780.223Desmo**/**Lano1.7400.9172.0321.1252.3100.7410.477Chol**/**Lano0.1350.0540.1490.0830.1620.0540.594Sito\*1000**/**Chol87.60429.851103.46751.266113.30638.7670.330Campe\*1000**/**CholNA---69.89255.70690.909---0.655Stigma\*1000/ Chol69.0483.36788.55151.38178.78817.1420.865Campe/ SitoNA---0.8890.1920.500---0.157Stigma/ Sito1.0000.0000.9170.1540.7500.3540.4317α-OHC/ Chol1.6190.9851.7201.4991.5701.1500.8507β-OHC/ Chol1.1300.5451.3430.9981.1990.5450.8497α-OHC/ 7β-OHC1.3860.2701.1860.4021.1760.4060.302Chol-L**/**Chol0.1600.0000.1890.1390.1920.0820.975Chol-M**/**Chol0.3050.0750.3400.1990.3340.0650.793Chol-P**/**Chol0.7910.2140.8320.5280.8260.1490.905Chol-O, LI, S**/**Chol0.8860.2850.9040.5831.0030.1530.492∑Cholesterol esters**/**Chol2.0020.5752.1541.3432.2190.3430.718^a^ND, not detected.^b^NA, not applicable.

Discussion {#Sec14}
==========

Novel findings of this study {#Sec15}
----------------------------

\(1\) In maternal serum, patients with preeclampsia had higher ratios of cholesterol/desmosterol and cholesterol/7-dehydrocholesterol (which represent 24- and 7-reductase enzyme activity, respectively) than those without preeclampsia, suggesting increased cholesterol biosynthesis; (2) In contrast, patients with preeclampsia had decreased ratios of individual cholesterol esters/cholesterol and total cholesterol esters/cholesterol than those without preeclampsia, suggesting increased reverse cholesterol transport; (3) no differences were found in cholesterol measurements and ratios in AF between patients with and without preeclampsia.

Interpretation of the result of the current study {#Sec16}
-------------------------------------------------

Although the association between preeclampsia and dyslipidemia has been previously described and is biologically plausible, it has not been a consistent finding in the literature^[@CR7]--[@CR9],[@CR20],[@CR21]^. In the largest report, a 2014 meta-analysis incorporating 74 studies, preeclampsia was associated with dyslipidemia including elevated total cholesterol, non-HDL (high density lipoprotein) cholesterol, and triglyceride levels during all trimesters of pregnancy^[@CR10]^. However, other investigators could not find association between preeclampsia and lipid and/or lipoprotein levels^[@CR22],[@CR23]^.

In the current study, cholesterol biosynthesis was increased and reverse cholesterol transport was also increased in women with preeclampsia. However, levels of free (biologically active) cholesterol in the maternal circulation were not different among the three groups of cases. This contrast result may be explained by two points of view. First, this negative result in the level of cholesterol may be originated from the small number of cases. Second, these findings suggest that metabolic profiling of cholesterol might detect subtle changes in cholesterol metabolism, and that such changes may be evident even before the onset of definite changes in cholesterol concentration in maternal blood. Indeed several other studies did not find significant correlation between cholesterol levels and preeclampsia^[@CR22],[@CR23]^.

Possible mechanism of altered cholesterol metabolism {#Sec17}
----------------------------------------------------

Several mechanisms can be proposed to explain the association between cholesterol metabolic change and preeclampsia. First, dyslipidemia may result from excessive oxidative stress leading to generalized endothelial dysfunction, which is the pathogenic hallmark of preeclampsia^[@CR24]^. Moreover, accumulation of lipid within the endothelial cell lining of the maternal spiral arteries may impair normal trophoblast invasion, possibly by altering prostaglandin production^[@CR25],[@CR26]^. Second, both dyslipidemia and preeclampsia are associated with the development of metabolic syndrome and related vascular disorders^[@CR27]^. Lastly, obesity may be the linking mechanism between dyslipidemia and preeclampsia. The biochemical markers of obesity were altered in women with preeclampsia, suggesting sharing mechanism among obesity, preeclampsia, and long-term cardiovascular disease^[@CR28]^.

Regarding the risk of preeclampsia, several recent studies have reported the changes in cholesterol homeostasis and metabolism. HDL cholesterol efflux capacity (the ability of HDL to remove cholesterol from macrophages) has been reported as a new biomarker for cardiovascular risk, and also as a biomarker for preeclampsia^[@CR29],[@CR30]^. Accelerated lipid metabolism outbalancing remnant removal mechanisms has been suggested as the contributor to the endothelial dysfunction in preeclampsia^[@CR31]^. The relationship between altered cholesterol homeostasis/ metabolism and preeclampsia should be evaluated in further studies.

The strength and limitation of the current study {#Sec18}
------------------------------------------------

Management guidelines published by the Society for Maternal-Fetal Medicine (SMFM) in 2011 recommend that women with severe preeclampsia (without an absolute indication for imminent delivery) be delivered at or after 34 weeks of gestation^[@CR32]^. As such, most cases of severe preeclampsia are delivered in the late preterm period. To fully understand the pathophysiologic changes in biologic samples collected from women with preeclampsia, appropriate control samples are needed for comparison; however, most healthy pregnant women are delivered at term. Most studies that have examined the pathophysiologic changes in biomaterials such as AF or placenta collected from women with preeclampsia have designated women who delivered preterm (after spontaneous preterm labor or preterm premature rupture of membranes) as the most appropriate controls. However, this may result in difficulty in interpreting the results, because differences could be explained by the presence of preeclampsia or by the pathologic mechanism that led to the spontaneous preterm parturition. To minimize this issue, we included as controls for preeclampsia not only women who deliver because of spontaneous preterm labor, but also women who delivered in the late preterm period because of maternal medical indications. In the current study, we did not evaluate women who delivered term neonates. They would have been true controls, but they would have not been matched for gestational age, also resulting in difficulty in the interpretation of the result when comparing with preeclamptic women who ended up in preterm birth.

Preeclampsia is known as heterogeneous disease with various clinical spectrums. In the current study, we included only preeclamptic women who delivered at late preterm period. Therefore women with early onset preeclampsia with severe feature that needed urgent delivery before 34 weeks of gestation were not included. In addition, the frequency of small for gestational age was 14.3%, suggesting that the primary feature of preeclampsia in the current study is mainly maternal condition rather than fetal growth impairment. More studies are needed to evaluate the cholesterol metabolism and various features of preeclampsia.

In addition, there were 14 cases with preeclampsia, including 11 cases with severe preeclampsia and 3 cases with non-severe preeclampsia. In terms of severity of preeclampsia, the changes of metabolic profiling were more pronounced in women with severe versus non-severe preeclampsia (data not shown), although there is not really enough power to make any firm conclusions from this because of small number of cases with non-severe preeclampsia.

Although the present retrospective study was conducted with plasma and amniotic fluid obtained from pregnant women, who were delivered between 1999 and 2007, most steroids including cholesterol may be good enough to be quantified even after more than 10 years under −25 °C storage^[@CR32]^, while oxysterols^[@CR33]^ are still considerable for long-term storage at −70 °C.

Suggestion for further studies {#Sec19}
------------------------------

In the current study, we could not measure the total cholesterol, HDL, LDL, VLDL, and triglyceride in maternal blood and amniotic fluid. The measurement of these components and evaluation the relationship between cholesterol metabolic profiling and dyslipidemia would be of great help in the interpretation of the current study result. As the association between preeclampsia and dyslipidemia is not well established, more studies are needed in this issue.

In contrast to the altered metabolism of cholesterol in maternal blood, the cholesterol metabolic profiling did not show any difference in amniotic fluid. This finding is inconsistent with the result in cord blood, in which HDL and total cholesterol were lower and atherogenic incidies were increased in neonates with growth restriction^[@CR33]^. As preeclampsia and fetal growth restriction are known to share the similar pathogenesis, defective placental invasion, the cholesterol metabolic profiling of cord blood will be also needed.

In recent reports, lipid-lowering agents such as pravastatin or simvastatin were reported as a therapeutic candidate for preeclampsia pathogenesis, because these medications reduced secretions of anti-angiogenic mediators such as sFlt-1^[@CR34],[@CR35]^. The altered cholesterol metabolism and application of these lipid-lowering agents should be evaluated in further studies.

Conclusion {#Sec20}
==========

The quantitative metabolic signatures of cholesterol suggest increased both cholesterol biosynthesis and accumulation by reverse cholesterol transport from cholesteryl esters in maternal blood (but not amniotic fluid) of women with preeclampsia.
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